Galecto is a clinical-stage biopharma focused on creating first-in-class treatments for cancer and liver diseases. Through its acquisition of Damora Therapeutics, Galecto has added a portfolio of antibody therapies that target mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is a potentially best-in-class anti-mutCALR monoclonal antibody engineered for subcutaneous dosing and is expected to file an IND in mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. Two additional antibodies, DMR-002 and DMR-003, are slated to enter Phase 1 studies thereafter. Galecto’s legacy pipeline also includes GB3226, a dual ENL-YEATS and FLT3 inhibitor being advanced toward an IND submission in Q1 2026 for acute myeloid leukemia. Following the $284.9 million private placement completed alongside the Damora acquisition, management projects a cash runway into 2029, sufficient to reach multiple clinical readouts. After conversion of the new preferred shares, Galecto will have 61,998,882 common shares outstanding.

Total raised

$154M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2020